Test Price
2,800 AED✅ Home Collection Available
TPM1 Gene Sequencing for Familial Hypertrophic Cardiomyopathy Type 3 (NGS) in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Diagnostic Precision & Service Excellence
This TPM1 sequencing test, performed at our DHA-licensed facility (License No. 1143), achieves 99.9% diagnostic sensitivity for familial hypertrophic cardiomyopathy type 3 using ISO 9001:2015-certified Next-Generation Sequencing. We offer VIP Mobile Phlebotomy with temperature-controlled cold-chain home collection daily from 8 AM to 11 PM, direct insurance verification via WhatsApp (+971 54 548 8731), and post-test clinical guidance by Consultant Medical Genetics Lina Osama Zaki Quteineh (DHA ID: 9294403).
Test Overview & Methodology
This test analyzes the entire TPM1 gene using next-generation sequencing to detect pathogenic variants linked to familial hypertrophic cardiomyopathy type 3. It provides a definitive diagnosis for patients and families at risk, guiding personalized cardiac management and surveillance. The methodology covers coding and regulatory regions, ensuring comprehensive variant detection.
| Feature | Our Test (NGS Full Gene) | Closest Alternative (Sanger Single Gene) |
|---|---|---|
| Methodology | Next-Generation Sequencing (NGS) | Sanger Sequencing (targeted) |
| Coverage | Entire gene (coding + regulatory regions) | Only selected exons / known mutations |
| Sensitivity | 99.9% | <95% for novel variants |
| Turnaround Time | 3 – 4 Weeks | 6 – 8 Weeks |
| Accreditation | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) | Variable / Not guaranteed |
Physician Insight & Safety Protocols
Clinical Perspective – Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA ID: 9294403):
Genetic test results for hypertrophic cardiomyopathy must be evaluated within the context of your personal and family cardiac history. A positive finding indicates an increased risk, not a certainty. I strongly recommend discussing all results with a certified genetic counselor to guide informed family screening and preventive strategies.
Advisory: Medication Continuity & Safety
Do NOT stop any prescribed cardiac or blood-thinning medication without consulting your treating physician. Abrupt discontinuation may precipitate life-threatening arrhythmias or heart failure.
Exclusion Criteria & Emergency Red Flags
- Recent blood transfusion (<2 weeks) or active systemic infection may affect DNA quality; please reschedule.
- Patients with acute decompensated heart failure or unstable angina should not undergo elective blood draws until stabilized.
- Urgent symptoms: If you experience sudden chest pain, fainting, or severe shortness of breath, seek emergency medical attention immediately — do not wait for genetic results.
Patient FAQ & Clinical Guidance
1. What does the TPM1 gene test detect?
Direct answer: The test identifies pathogenic DNA variants in the TPM1 gene that cause familial hypertrophic cardiomyopathy type 3. It screens for mutations altering the tropomyosin protein, a key regulator of cardiac muscle contraction, which can lead to abnormal heart muscle thickening and electrical instability.
2. How should I prepare for the blood collection?
Direct answer: Avoid strenuous exercise for 24 hours and stay hydrated; no fasting is required. Our mobile phlebotomist will collect a small blood sample or an FTA card spot. Please have your Emirates ID and insurance card ready. A pre-test genetic counseling session is recommended to map your family pedigree.
3. How will my doctor use the results?
Direct answer: Results guide personalized screening, family planning, and targeted therapies for hypertrophic cardiomyopathy. A positive finding may prompt echocardiograms, Holter monitoring, or preventive medication for at-risk relatives. It also supports reproductive decisions through IVF with preimplantation genetic diagnosis.
UAE Regulatory & Data Privacy Adherence
Your genetic data privacy is protected under the Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. All laboratory processes are governed by ISO 9001:2015 certificate INT/EGQ/2509DA/3139.
Clinical & Logistical Metadata
| Test Name | TPM1 Gene Sequencing for Familial Hypertrophic Cardiomyopathy Type 3 (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 15 – 20 Business Days |
| Sample Type / Matrix | Peripheral Whole Blood (FTA Card acceptable) |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Gene Coverage |
| ICD-10-CM Code | I42.1 (Obstructive hypertrophic cardiomyopathy), I42.2 |
| LOINC Code | 94212-9 |
| DHA Facility License & Address | Lic. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians